Understanding how we might replace damaged and diseased tissue through the use of stem cell based therapies is an important goal for biomedical science.
The completion of the swine genome is providing the platform for discovering which genes are responsible for various genetic diseases, as well as the tool for recreating these mutations in swine such as the increased use of cell based transgenesis in a site specific manner.
With the sequenced pig genome, the use of cell based transgenesis will become a new approach to make genetically modified pigs.
The objective of our research efforts is to substantively improve drug delivery through the use of cell based carriers for tumors and microbial infection, in particular HIV [1].
Use of cell based therapies for T1D will still need to overcome or bypass autoimmunity.
We hereby wanted to identify potential targets or factors, which could prove effective in treating malignant gliomas without the use of cell based therapy.
Recently, MSCs have been suggested for use in the cell based treatment of cartilage lesions.
The SPCPM algorithm outperforms other methods due to the use of a cell-based structure which decreases the contentions during the workload increase.
A major strength of our study is the use of a cell-based assay, the DR-CALUX assay, to measure the total concentration of DLCs in plasma samples of participants.
Our use of a cell-based assay that functionally expressed the Leu723Gln CaSR mutant, revealed the gain-of-function associated with the Leu723Gln mutation to be wholly responsive to NPS 2143.
In November 2002, in what was only the second research article to be published by the Journal of Biology, Jeff Porter and colleagues described their use of a cell-based assay to identify and characterize small molecules that modulate the activity of the Hedgehog signaling pathway [ 1].
